290 related articles for article (PubMed ID: 10708367)
1. InhA, a target of the antituberculous drug isoniazid, is involved in a mycobacterial fatty acid elongation system, FAS-II.
Marrakchi H; Lanéelle G; Quémard AK
Microbiology (Reading); 2000 Feb; 146 ( Pt 2)():289-296. PubMed ID: 10708367
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of the inhA-encoded fatty acid synthase II (FASII) enoyl-acyl carrier protein reductase induces accumulation of the FASI end products and cell lysis of Mycobacterium smegmatis.
Vilchèze C; Morbidoni HR; Weisbrod TR; Iwamoto H; Kuo M; Sacchettini JC; Jacobs WR
J Bacteriol; 2000 Jul; 182(14):4059-67. PubMed ID: 10869086
[TBL] [Abstract][Full Text] [Related]
3. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis.
Rozwarski DA; Grant GA; Barton DH; Jacobs WR; Sacchettini JC
Science; 1998 Jan; 279(5347):98-102. PubMed ID: 9417034
[TBL] [Abstract][Full Text] [Related]
4. Isoniazid affects multiple components of the type II fatty acid synthase system of Mycobacterium tuberculosis.
Slayden RA; Lee RE; Barry CE
Mol Microbiol; 2000 Nov; 38(3):514-25. PubMed ID: 11069675
[TBL] [Abstract][Full Text] [Related]
5. Slow-onset inhibition of 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis by an inorganic complex.
Oliveira JS; de Sousa EH; de Souza ON; Moreira IS; Santos DS; Basso LA
Curr Pharm Des; 2006; 12(19):2409-24. PubMed ID: 16842188
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of InhA activity, but not KasA activity, induces formation of a KasA-containing complex in mycobacteria.
Kremer L; Dover LG; Morbidoni HR; Vilchèze C; Maughan WN; Baulard A; Tu SC; Honoré N; Deretic V; Sacchettini JC; Locht C; Jacobs WR; Besra GS
J Biol Chem; 2003 Jun; 278(23):20547-54. PubMed ID: 12654922
[TBL] [Abstract][Full Text] [Related]
7. In vitro inhibition of the Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein reductase MabA by isoniazid.
Ducasse-Cabanot S; Cohen-Gonsaud M; Marrakchi H; Nguyen M; Zerbib D; Bernadou J; Daffé M; Labesse G; Quémard A
Antimicrob Agents Chemother; 2004 Jan; 48(1):242-9. PubMed ID: 14693546
[TBL] [Abstract][Full Text] [Related]
8. ACCase 6 is the essential acetyl-CoA carboxylase involved in fatty acid and mycolic acid biosynthesis in mycobacteria.
Kurth DG; Gago GM; de la Iglesia A; Bazet Lyonnet B; Lin TW; Morbidoni HR; Tsai SC; Gramajo H
Microbiology (Reading); 2009 Aug; 155(Pt 8):2664-2675. PubMed ID: 19423629
[TBL] [Abstract][Full Text] [Related]
9. Function of heterologous Mycobacterium tuberculosis InhA, a type 2 fatty acid synthase enzyme involved in extending C20 fatty acids to C60-to-C90 mycolic acids, during de novo lipoic acid synthesis in Saccharomyces cerevisiae.
Gurvitz A; Hiltunen JK; Kastaniotis AJ
Appl Environ Microbiol; 2008 Aug; 74(16):5078-85. PubMed ID: 18552191
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis, by triclosan and isoniazid.
Parikh SL; Xiao G; Tonge PJ
Biochemistry; 2000 Jul; 39(26):7645-50. PubMed ID: 10869170
[TBL] [Abstract][Full Text] [Related]
11. Fast-growing, non-infectious and intracellularly surviving drug-resistant Mycobacterium aurum: a model for high-throughput antituberculosis drug screening.
Gupta A; Bhakta S; Kundu S; Gupta M; Srivastava BS; Srivastava R
J Antimicrob Chemother; 2009 Oct; 64(4):774-81. PubMed ID: 19656786
[TBL] [Abstract][Full Text] [Related]
12. Conditional depletion of KasA, a key enzyme of mycolic acid biosynthesis, leads to mycobacterial cell lysis.
Bhatt A; Kremer L; Dai AZ; Sacchettini JC; Jacobs WR
J Bacteriol; 2005 Nov; 187(22):7596-606. PubMed ID: 16267284
[TBL] [Abstract][Full Text] [Related]
13. Determination of the primary target for isoniazid in mycobacterial mycolic acid biosynthesis with Mycobacterium aurum A+.
Wheeler PR; Anderson PM
Biochem J; 1996 Sep; 318 ( Pt 2)(Pt 2):451-7. PubMed ID: 8809032
[TBL] [Abstract][Full Text] [Related]
14. Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid.
Vilchèze C; Wang F; Arai M; Hazbón MH; Colangeli R; Kremer L; Weisbrod TR; Alland D; Sacchettini JC; Jacobs WR
Nat Med; 2006 Sep; 12(9):1027-9. PubMed ID: 16906155
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms for isoniazid action and resistance.
Miesel L; Rozwarski DA; Sacchettini JC; Jacobs WR
Novartis Found Symp; 1998; 217():209-20; discussion 220-1. PubMed ID: 9949810
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of inhA, but not kasA, confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M. bovis BCG and M. tuberculosis.
Larsen MH; Vilchèze C; Kremer L; Besra GS; Parsons L; Salfinger M; Heifets L; Hazbon MH; Alland D; Sacchettini JC; Jacobs WR
Mol Microbiol; 2002 Oct; 46(2):453-66. PubMed ID: 12406221
[TBL] [Abstract][Full Text] [Related]
17. Development of modern InhA inhibitors to combat drug resistant strains of Mycobacterium tuberculosis.
Tonge PJ; Kisker C; Slayden RA
Curr Top Med Chem; 2007; 7(5):489-98. PubMed ID: 17346194
[TBL] [Abstract][Full Text] [Related]
18. Probing mechanisms of resistance to the tuberculosis drug isoniazid: Conformational changes caused by inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis.
Kruh NA; Rawat R; Ruzsicska BP; Tonge PJ
Protein Sci; 2007 Aug; 16(8):1617-27. PubMed ID: 17600151
[TBL] [Abstract][Full Text] [Related]
19. MabA (FabG1), a Mycobacterium tuberculosis protein involved in the long-chain fatty acid elongation system FAS-II.
Marrakchi H; Ducasse S; Labesse G; Montrozier H; Margeat E; Emorine L; Charpentier X; Daffé M; Quémard AK
Microbiology (Reading); 2002 Apr; 148(Pt 4):951-960. PubMed ID: 11932442
[TBL] [Abstract][Full Text] [Related]
20. The Molecular Genetics of Mycolic Acid Biosynthesis.
PaweŁczyk J; Kremer L
Microbiol Spectr; 2014 Aug; 2(4):MGM2-0003-2013. PubMed ID: 26104214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
